| Today’s Big NewsApr 10, 2024 |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
| By Annalee Armstrong A session at the American Association for Cancer Research annual meeting asked a key question: Are cancer vaccines ready for prime time? If you ask Scott Kopetz, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, the answer is a quick yes. |
|
|
|
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
By Kevin Dunleavy In response to recent FDA guidelines which limit the nitrosamine content of drugs, Novartis has paused the enrollment of early breast cancer (eBC) patients in clinical trials of its blockbuster Kisqali (ribociclib) as it makes adjustments to its manufacturing processes for the drug. |
By Gabrielle Masson On the heels of Relyvrio’s market withdrawal in amyotrophic lateral sclerosis, Amylyx Pharmaceuticals has shared early data from a phase 2 trial in a separate rare disease that the biotech is touting as “clinically meaningful.” |
|
Tuesday, April 23, 2024 | 1pm ET / 10am PT Join us as we dive into the pivotal challenges facing clinical trial enrollment today. Learn about innovative strategies and solutions for quickly identifying the right patients for specific therapies, the optimal time in their health journey to engage, and how to successfully activate them for trial enrollment. Register now. 
|
|
By Fraiser Kansteiner “We can confirm that Nick Shipley’s last day with the Biotechnology Innovation Organization was April 5,” BIO said over email Wednesday. Shipley, who joined the organization in 2021, acted as BIO’s chief advocacy officer—a role in which he oversaw federal and state affairs related to the industry, including issues like government efforts to rein in drug prices. |
By Conor Hale A federal court has ordered Philips to restrict production, sales and exports of its CPAP and BiPAP machines, the culmination of a years-long international recall and repair effort. |
By Andrea Park While her first spot for the Big Pharma showed Gaga in her natural element, performing onstage for a crowd of cheering fans, this time around, the superstar summons her inner paparazzo to go behind the camera. |
By James Waldron For companies exploring the antibody-drug conjugate arena, the interest from Big Pharma and big-pocketed investors appears to be as strong as ever. |
By Angus Liu New data have come forward pointing to a link between achieving undetectable minimal residual disease (MRD) and improved treatment outcomes in multiple myeloma. The FDA appears receptive to the idea of using the measurement to support accelerated approvals of new drugs, even though the agency has a few questions. |
By Andrea Park Perrigo’s Opill birth control medication, which kicked off over-the-counter sales in the U.S. just last month, has a new teammate. |
By Zoey Becker While AstraZeneca CEO Pascal Soriot's pay package has attracted criticism ahead of the company's annual meeting, a large investor has come in to support the compensation plan, The Financial Times reports. In fact, GQG Partners' Rajiv Jain believes Soriot is "massively underpaid," according to the newspaper. |
By Annalee Armstrong Why haven’t CAR-T therapies cracked into solid tumors yet? Poseida Therapeutics is trying to fill in at least one piece of the puzzle with a new analysis presented at the American Association for Cancer Research. |
By Nick Paul Taylor UCB wants to help patients “Make HStory.” The Belgian drugmaker is launching the campaign, including a 30-second video, to raise awareness of the reality of living with the chronic skin condition hidradenitis suppurativa. |
By Joseph Keenan Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to produce lomustine, which is used to treat brain tumors. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged. |
|
|---|
|
|
|
Tuesday, April 30, 2024 | 2pm ET / 11am PT Liquid biopsies have shown tremendous progress for the early detection of cancer and for treatment monitoring, but still have limitations. The inclusion of protein glycosylation can help. Join us to learn more about the latest solutions for leveraging AI and machine learning to accelerate data processing, overcome current barriers, and provide crucial information. Register now. 
|
|
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
